NEW YORK CITY, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ:RGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Regenxbio and certain of its officers and/or directors […]

NEW YORK, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Vizsla Silver Corp. ("Vizsla Silver" or the "Company") (NYSE:VZLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Vizsla Silver and certain of its officers

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Cogent Communications Holdings, Inc. ("Cogent" or the "Company") (NASDAQ:CCOI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Cogent and certain of its officers

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of New Era Energy & Digital, Inc. ("New Era" or the "Company") (NASDAQ:NUAI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether New Era and

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ:RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ:MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Nutanix, Inc. ("Nutanix" or the "Company") (NASDAQ:NTNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nutanix and certain of its officers and/or directors

NEW YORK, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Corcept and certain of its officers and/or directors

NEW YORK, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Instil and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of AST SpaceMobile, Inc. ("AST" or the "Company") (NASDAQ:ASTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether AST and certain of its officers and/or